Document Type : Original Article

Authors

1 Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Gynecology Oncology Division, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

3 Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4 Core Medical Trainee, Northumbria Healthcare NHS Foundation Trust, Newcastle upon Tyne, U.K.

Abstract

Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used to treat peritoneal carcinomatosis (PC). The objective was to evaluate the outcomes of cytoreductive surgery (CRS) and HIPEC in our center.
Method: In this retrospective study, data were collected from 43 patients with PC who underwent CRS-HIPEC in 2016 at Faghihi Hospital of Shiraz University of Medical Sciences. Outcomes were collected and analyzed. Analyses were conducted through SPSS 23. P-value < 0.05 was considered to be statistically significant.
Results: The mean age of the patients was 52.23 پ} 11.82 years. The participants in the study analysis consisted of 36 female (83.7%) and seven male patients (16.3%). The most common primary tumor was ovarian cancer (62.8%). Completeness of the cytoreduction score of CC0/CC1 was obtained in 87.7% of the patients. The 1- and 3- year overall survivals were 88% and 60%, respectively.
Conclusion: Our study supports that employing CRS and HIPEC for PC is feasible with acceptable morbidity in our center.

Keywords

How to cite this article:

Akrami M, Khezri S, Tahmasebi S, Karami MY, Shiravani Z, Zangouri V, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: Initial report from Shiraz surgical oncology group. Middle East J Cancer. 2022;13(3):458-65. doi: 10.30476/mejc.2021.87830.1440.

  1. Sugarbaker PH. Prevention and treatment of peritoneal metastases: a comprehensive review. Indian J Surg Oncol. 2019;10(1):3-23. doi: 10.1007/s13193-018-0856-1.
  2. Nikeghbalian S, Nikoupour H, Dehghani M, Karami MY, Hemati R. Cytoreductive surgery and hyperthermic intraoperative chemotherapy for management of peritoneal carcinomatosis. Arch Iran Med. 2018;21(4):158-63.
  3. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7(1):69-76. doi: 10.1016/S1470-2045(05)70539-8.
  4. Sugarbaker PH, Turaga KK, Alexander HR Jr, Deraco M, Hesdorffer M. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016;12(10):928-935. doi: 10.1200/JOP.2016.011908.
  5. Aoyagi T, Terracina KP, Raza A, Takabe K. Current treatment options for colon cancer peritoneal carcinomatosis. World J Gastroenterol. 2014;20(35):12493. doi: 10.3748/wjg.v20.i35.12493.
  6. Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460. doi: 10.1200/JCO.2014.55.9898.
  7. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(2):327-33.
  8. Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12(5):351-5. doi:10.1007/s00534-005-0999-7.
  9. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14(3):254-61. doi: 10.1002/(sici)1098-2388(199804/05)14:3<254::aid-ssu10>3.0.co;2-u.
  10. Carmignani CP, Esquivel J, Sugarbaker PH. Cytoreductive surgery and intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. Revista de Oncología. 2003;5(4):192-8.
  11. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205. doi: 10.1097/01.sla.0000133083.54934.ae.
  12. Muñoz-Casares FC, Medina-Fernández FJ, Arjona-Sánchez Á, Casado-Adam Á, Sánchez-Hidalgo JM, Rubio MJ, et al. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center. Eur J Surg Oncol. 2016;42(2):224-33. doi: 10.1016/j.ejso.2015.11.006.
  13. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early-and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449-56. doi: 10.1200/JCO.2011.39.7166.
  14. Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg oncol. 2015;22(5):1686-93. doi: 10.1245/s10434-014-3978-x.
  15. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370-7.
  16. Spiliotis J, Halkia E, De Bree E. Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy—current perspectives. Curr Oncol. 2016;23(3):e266. doi:10.3747/co.23.2831.
  17. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018;378(3):230-40. doi: 10.1056/NEJMoa1708618.
  18. Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578-89. doi: 10.1016/j.ejso.2015.08.172.
  19. Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis. Eur J Surg Oncol. 2019;45(3):301-9. doi: 10.1016/j.ejso.2018.10.528.
  20. Robella M, Vaira M, Cinquegrana A, De Simone M. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: morbidity and postoperative outcomes. Minerva Chir. 2019;74(3):195-202. doi: 10.23736/s0026-4733.18.07649-6.
  21. Piso P, Nedelcut SD, Rau B, Königsrainer A, Glockzin G, Ströhlein MA, et al. Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Data from the DGAV StuDoQ registry with 2149 consecutive patients. Ann Surg Oncol. 2019;26(1):148-54. doi: 10.1245/s10434-018-6992-6.